Health Technology Assessment in South Africa: Towards NHI

By João L. Carapinha

June 4, 2024

Introduction

There are plans to implement Health Technology Assessment in South Africa on a wide scale. This will make sure that all HTA processes are standardized with the aim of using them for prioritizing areas where funds need to be allocated thus achieving fairness and effectiveness at the same time under National Health Insurance system. Although there have been some initiatives already carrying out HTAs, they lack continuity. By establishing a Ministerial Advisory Committee for HTA, the country hopes that creation of an independent and strong entity will assist on advising decision makers in the health sector.

The Development of Health Technology Assessment in South Africa

HTA has evolved in South Africa mainly through selection of Essential Medicines for the NEML (National Essential Medicine List). The latter guides procurement within public institutions and public health programs rely heavily on it. However different bodies perform HTA functions leading to duplication hence inefficiency. The NEML Committee historically concentrated much on evaluating drugs without adequate resources allocated towards this end. Additional efforts are also needed to strengthen the evidence-based approach to broadened the scope to include various medical devices and procedures.

Health Technology Assessment in South Africa
Source: Institutionalizing Health Technology Assessment in South Africa—An Opportunity in National Health Insurance.

The Significance of HTA under NHI

According to the NHI design, there should be a framework for HTA which starts at ministerial level before expanding into a national entity. This new body shall use scientific methods when assessing different healthcare interventions so that resources can be fairly distributed among them. The passing into law of the NHI Bill in 2024 marks significant progress. The post approval phase will involve HTAs being used to define a cost effective benefit package as well as shaping strategic purchasing decisions. It is also planned that this model should start off small but expand over time to ensure it’s sustainable implementation.

Strategies for Effective Implementation

For HTA to become a fixed part of the way things are done, current systems must be utilized. The first step is to create the Ministerial Advisory Committee and establish HTA policy frameworks. Secondly, contracting and involving stakeholders will be used to strengthen national HTA resources in the medium term. In the long run, the NHI should operationalize HTA processes to a level where they may become an independent body. This will mean investment in human resource capacity building, governance structures as well collaborative relationships with academic institutions.

Conclusion

Using HTA systematically under the NHI could lead to more efficient investment in healthcare. Clear methods for decision-making should be used when resource allocation decisions are involved. The successful incorporation of HTA into the NHI framework will depend on strong leadership, stakeholder collaboration, and ongoing commitment to capacity building. Ensuring equitable access to quality healthcare for all South Africans will ultimately validate the efforts to institutionalize HTA.

Reference url

Recent Posts

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

value-based drug pricing
      

Optimizing Value-Based Drug Pricing in Japan with MARIE Framework

🔍 Are we pricing drugs based on true value?

The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.

Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.